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higher medical costs in six European settings. METHODS: The Archimedes model
was used to simulate cohorts of individuals ages 40 to 75 with no prior history of
diabetes, cardiovascular disease, or chronic kidney disease, in Denmark, France,
Germany, Italy, Poland and the UK. Individuals were simulated for 10 years and the
incidences of diabetes and MACE were tracked, along with mean total medical
costs per person. A risk score was computed for each simulated person, with base-
line data on age, gender, BMI, waist, smoking, family histories of diabetes and
cardiovascular disease, and antihypertensive usage. For each country, the sub-
populations of individuals with above median risk score (TOP50), and individuals in
the top risk score quartile (TOP25) were compared to the full cohorts. RESULTS:
Diabetes and MACE incidences were higher in the TOP50 and TOP25 subgroups, as
were total medical costs. In each country, the mean 10-year discounted medical
costs for the full cohorts vs. the TOP50 subgroups were: Denmark €8,482 (95%CI
8,027 - 8,937) vs. €11,292 (10,614 - 11,969); France €6,264 (5,917 - 6,611) vs. €8,492
(7,953 - 9,031); Germany €8,717 (8,218 - 9,217) vs. €11,974 (11,204 - 12,743); Italy €7,688
(7,273 - 8,104) vs. €10,279 (9,643 - 10,914); Poland €1,798 (1,707 - 1,888) vs. €2,418
(2,274 - 2,561); UK €4,100 (3,885 - 4,314) vs. €5,580 (5,238 - 5,921). Medical costs were
even higher in the TOP25 subgroup. CONCLUSIONS: This risk score could be an
effective tool for identifying individuals likely to incur higher health care costs due
to diabetes and MACE. Targeting individuals with such scores could make screen-
ing programs more efficient, provided validation in real-world populations.
PCV23
BETA BLOCKERS FOR TREATMENT OF CHRONIC HEART FAILURE IN SPAIN:
REVIEW OF THE ECONOMIC EVIDENCE AND EFFICIENCY ANALYSIS
Polanco C, García-Jurado L
Merck SL, Madrid, Spain
OBJECTIVES: Chronic heart failure (CHF) is a major health issue because of its
growing prevalence, morbimortality and associated resource consumption. Beta
blockers have been shown to be effective and cost-effective therapies for CHF. The
aim is determining what beta blocker constitutes the most efficient therapy for CHF
patients in Spain. METHODS: Systematic review of primary (clinical trials) and
secondary (meta-analyses, clinical practice guidelines and economic assessments)
evidence on beta blockers for CHF issued before May 2012. Once that efficacy of
each beta blocker was established, local drug databases were accessed in order to
estimate the updated annual cost of each therapy and daily dose in Spain.
RESULTS: Given their similar efficacy [death RR: bisoprolol: 0.66, p0.0001; meto-
prolol: 0.66, p0.0001; carvedilol: 0.65, p0.005, nebivolol: 0.88, p0.21] and safety
profiles, international clinical guidelines on Cardiology recommend bisoprolol,
metoprolol succinate, carvedilol and nebivolol as first choice therapies for CHF
(class I and level of evidence A). Annual treatment costs per patient reached 38.70€;
162.53-311.69€; 170.70€ and 188.14€ for bisoprolol, carvedilol, metoprolol succinate
and nebivolol, respectively. When hospitalization costs are considered, cost per
avoided death was 9.512€, 14.989€, 16.767€ and 50.795€ for bisoprolol, carvedilol,
metoprolol succinate and nebivolol, respectively. Results of the cost-benefit anal-
ysis indicated that only bisoprolol showed a net benefit, with an estimated annual
savings of 116.293€. Budget impact analysis yields that bisoprolol implies a saving
of 76-88% of carvedilol cost of therapy per year and patient, 77% when compared to
metoprolol succinate and 79% versus nebivolol. CONCLUSIONS: Despite the unde-
ruse of betablockers for CHF treatment, they have demonstrated to be effective and
cost-effective. Among them, bisoprolol gathers pharmacologic, legal and phar-
macoeconomic characteristics that confirm their being the most efficient beta
blocker (both in terms of cost-benefit and cost-effectiveness) for CHF patients in
Spain.
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OBJECTIVES: New anti-thrombotic strategy with recent low-molecular-weight
heparins (LMWHs) used for the prevention of symptomatic deep venous thrombo-
sis and pulmonary embolism (DVT/PE) has shown clinical and outcome benefits in
patients undergoing orthopedic surgery. The purpose of our study is to analyze the
costs of LMWHs in total knee replacement and to compare cost-effectiveness and
budget impact of bemiparin and enoxaparin addition to current treatment of such
patients in Russia. METHODS: Cost-effectiveness analysis and budget impact
model of patients with total knee replacement (n1000) is used to compare alter-
native strategies with bemiparin and enoxaparin for deep venous thrombosis and
pulmonary embolism prevention. The model calculates the budget impact of in-
hospital LMWHs drug therapy change for these patients. Only direct costs of med-
icines were considered. The prices of medications were taken from the official price
listing. Rates of main outcome were based on literature data (confirmed venous
thromboembolism 32.1% for bemiparin and 36.9% for enoxaparin). Net budget im-
pact was expressed as a difference in costs between the strategies where bemiparin
is gradually elevated versus traditionally enoxaparin prevention. The budget im-
pact is reported in terms of additional annual total costs. RESULTS: According to
the model, prevention of DVT/PE with bemiparin in total knee replacement was
dominant when compared to enoxaparin. Scenario of the introduction of bemi-
parin reduces budget costs for LMWHs drugs (in case 50% bemiparin and 50%
enoxaparin for 130.9 RUB / patient). In case of 100% bemiparin it can provide actual
DVT/PE prevention in 117 additional patients with total knee replacement.
CONCLUSIONS: Bemiparin demonstrated optimal cost-effectiveness and budget
savings compared to enoxaparin in total knee replacement. Further steps such as
including bemiparin in clinical recommendations and medical standards of care
for the patients is needed for implementing bemiparin in routine hospital practice.
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OBJECTIVES: Evidence on the use of newer antiplatelet agents and their cost im-
plications remains scarce. Previous research has shown a shorter average hospital
length of stay for prasugrel-treated patients compared to clopidogrel-treated pa-
tients. We analyzed a large geographically diverse database from the US and com-
pared cost of hospitalization for patients with acute coronary syndrome (ACS) who
have undergone percutaneous coronary intervention (PCI) and who received either
clopidogrel or prasugrel. METHODS: Using a large representative US database
maintained by PREMIER, we analyzed patient characteristics and total hospitaliza-
tion costs during the index (first) hospitalization among ACS-PCI patients treated
with clopidogrel or prasugrel between July 2009 and June 2011. Analysis included
patients treated with prasugrel who were on-label and clopidogrel-treated patients
who would have been eligible for prasugrel treatment per the label. Observed costs
were analyzed unadjusted and adjusted for baseline differences using a general-
ized linear model with a gamma distribution and log link function with propensity
score stratification. RESULTS:Data were available for 75,315 patients who received
clopidogrel and 9,483 patients who received prasugrel during their hospitalization.
The observed mean hospitalization costs (SD) for clopidogrel and prasugrel, respec-
tively, were $17,519 ($2,548) and $17,136 ($2,562). Mean costs for clopidogrel and
prasugrel recipients, respectively, were $16,937 ($2,162) and $16,664 ($2,137) for
STEMI, $17,926 ($2,747) and $17,511 ($2,849) for NSTEMI, and $17,900 ($2,665) and
$17,393 ($2,676) for UA (all comparisons, P0.001). The adjusted results showed
prasugrel-treated patients cost as much as $882 less than clopidogrel-treated pa-
tients (P0.001) during the index hospital stay. CONCLUSIONS: Prasugrel-treated
patients used fewer health care resources compared to clopidogrel-treated pa-
tients during the index hospital stay, as measured by hospital costs. Similar results
were obtained after adjusting for patient demographics and clinical characteris-
tics. The potential for unmeasured confounder bias is a limitation in this real-world
observational research.
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OBJECTIVES:The PLATO trial showed that ticagrelor reduced the risk of myocardial
infarction, stroke or death from vascular causes compared to clopidogrel (hazard
ratio 0.84, 95% CI 0.77 to 0.92) without a significant increase in major bleeding. The
objective of this analysis is to evaluate direct and indirect costs of ticagrelor versus
branded clopidogrel in patients with acute coronary syndromes (ACS) from a Rus-
sian health care perspective. METHODS: An excel based model was developed to
estimate the direct and indirect cost per treatment arm for specific CV events (non
fatal MIs, CV deaths and other deaths). Rates of non fatal myocardial infarction
(MI), CV death and death from other causes was extracted from the PLATO trial
(NCT00391872). Difference in direct medical and non-medical costs for ticagrelor vs
clopidogrel in patients was estimated using the events above. One-way sensitivity
analysis was performed. RESULTS: The result of this analysis shows that ticagrelor
is associated with reduced health care costs compared with branded clopidogrel for
one year treatment in a Russian health care setting. The incremental drug costs of
ticagrelor (- 264.46 RUB (€6.48) per patient per year) was offset by higher non drug
costs associated with fewer MI’s and deaths. Treatment with ticagrelor for one year
is associated with total cost savings of 2749.97 RUB (€67.37) per patient, the direct
cost savings was of 1260.83 (€30.89) and the indirect was 1489.13 RUB (€36.48) Sen-
sitivity analysis showed that ticagrelor remains to be cost saving compared to
branded clopidogrel as long as the ticagrelor price is less than 3520.94 RUB (€86.25)
per package while keeping other model parameters unchanged. CONCLUSIONS:
This analysis demonstrates that one year treatment with ticagrelor is less costly
than branded clopidogrel for patients with ACS from a Russian health care perspec-
tive.
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OBJECTIVES: Two approaches recanalization or restoration of adequate perfusion
and neuroprotection are identified as a pathogenic treatment of acute ischemic
stroke (AIS). Timely mechanical revascularization and thrombolytic therapy pre-
vent the development of neurons necrosis and significantly improve survival and
quality of patient life. Unfortunately, in Ukraine these methods are difficult of
access for patients due to high cost, late diagnostics and contraindications. The
A366 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
